多参数磁共振成像在前列腺癌主动监测中的应用研究进展

摘要
图/表
参考文献(0)
相关文章 (9)

全文: PDF (831 KB) HTML (1 KB)
输出: BibTeX | EndNote (RIS)

摘要主动监测作为低风险局限性前列腺癌患者的一种管理选择，旨在降低过度治疗、减少治疗成本，并提高患者的生活质量。然而，在我国，该治疗策略的全面应用仍面临许多障碍，如筛选标准、监测流程和积极干预指征的制定等方面仍有待完善。多参数磁共振成像（mp-MRI）在前列腺癌主动监测中发挥着越来越重要的作用，它能提供有关前列腺癌识别（如PI-RADS评分系统）和特征（MRI靶向活检）的关键附加信息；通过改善前列腺癌风险分层，mpMRI可以增加低风险前列腺癌患者对主动监测的选择性和依从性；同时，在随访过程中，mp-MRI有助于监测疾病状态，降低错过治疗时机的风险。本文综述mpMRI在前列腺癌主动监测中的应用及研究进展。

	服务

	把本文推荐给朋友
	加入我的书架
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章
	覃小燕1
	2
	彭鹏2

关键词 ：前列腺癌, 主动监测, 多参数磁共振成像, 风险分层

收稿日期: 2023-03-30

基金资助:广西壮族自治区卫生健康委员会计划课题（Z20200603）；广西医科大学高水平创新团队及杏湖学者计划资助

通讯作者: 彭鹏（通讯作者），医学博士，主任医师，E-mail：doublep@126.com

作者简介: 覃小燕（1982—），女，副主任医师，主要从事前列腺疾病及脑小血管疾病影像诊断；

引用本文:

覃小燕1,2，彭鹏2. 多参数磁共振成像在前列腺癌主动监测中的应用研究进展[J]. 江苏大学学报:医学版, 2023, 33(05): 386-390,443.

链接本文:

http://zzs.ujs.edu.cn/xbyxb/CN/ 或 http://zzs.ujs.edu.cn/xbyxb/CN/Y2023/V33/I05/386

［1］Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries\[J\]. CA Cancer J Clin, 2021, 71(3): 209-249.
［2］Liu JL, Patel HD, Haney NM, et al. Advances in the selection of patients with prostate cancer for active surveillance\[J\]. Nat Rev Urol, 2021, 18(4): 197-208.
［3］Silva Gaspar SR, Fernandes M, Castro A, et al. Active surveillance protocol in prostate cancer in Portugal\[J\]. Actas Urol Esp (Engl Ed), 2022, 46(6): 329-339.
［4］Wilt TJ, Ullman KE, Linskens EJ, et al. Therapies for clinically localized prostate cancer: a comparative effectiveness review\[J\]. J Urol, 2021, 205(4): 967-976.
［5］Tosoian JJ, Carter HB, Lepor A, et al. Active surveillance for prostate cancer: current evidence and contemporary state of practice\[J\].Nat Rev Urol, 2016, 13(4): 205-215.
［6］Rouviere O, Moldovan PC. The current role of prostate multiparametric magnetic resonance imaging\[J\]. Asian J Urol, 2019, 6(2): 137-145.
［7］Richenberg J, Lgager V, Panebianco V, et al. The primacy of multiparametric MRI in men with suspected prostate cancer\[J\]. Eur Radiol, 2019, 29(12): 6940-6952.
［8］Mahal BA, Butler S, Franco I, et al. Use of active surveillance or watchful waiting for lowrisk prostate cancer and management trends across risk groups in the united states, 2010—2015\[J\]. JAMA, 2019, 321(7): 704-706.
［9］Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries\[J\]. CA Cancer J Clin, 2018, 68(6): 394-424.
［10］Zhang K, Bangma CH, Roobol MJ. Prostate cancer screening in Europe and Asia\[J\]. Asian J Urol, 2017, 4(2): 86-95.
［11］Tosoian JJ, JohnBull E, Trock BJ, et al. Pathological outcomes in men with low risk and very low risk prostate cancer:implications on the practice of active surveillance\[J\]. J Urol, 2013, 190(4): 1218-1222.
［12］Parker PA, Davis JW, Latini DM, et al. Relationship between illness uncertainty, anxiety, fear of progression and quality of life in men with favourablerisk prostate cancer undergoing active surveillance\[J\]. BJU Int, 2015, 117(3): 469-477.
［13］魏永宝,刘龙飞,李鑫，等. 低危前列腺癌中国诊疗现状：全国范围的网络横断面调查\[C\]//中国中西医结合学会男科专业委员会.首届男性大健康中西医协同创新论坛暨第三届全国中西医结合男科青年学术论坛论文集.\[出版者不详\]. 2019. DOI:10.26914/c.cnkihy.2019.011482.
［14］Boesen L. Multiparametric MRI in detection and staging of prostate cancer\[J\]. Dan Med J, 2017, 64(2): B5327.
［15］Ahmed HU, ElShater Bosaily A, Brown LC, et al. Diagnostic accuracy of multiparametric MRI and TRUS biopsy in prostate cancer(PROMIS): a paired validating confirmatory study\[J\]. Lancet, 2017, 389(10071): 815-822.
［16］Lam TBL, MacLennan S, Willemse PM, et al. EAUEANMESTROESURSIOG Prostate cancer guideline panel consensus statements for deferred treatment with curative intent for localised prostate cancer from an international collaborative study(DETECTIVE Study)\[J\]. Eur Urol, 2019, 76(6): 790-813.
［17］Turkbey B, Rosenkrantz AB, Haider MA, et al. Prostate imaging reporting and data system version 21: 2019 update of prostate imaging reporting and data system version 2\[J\]. Eur Urol, 2019, 76(3): 340-351.
［18］郭吉锋,纪志英,解丙坤,等.T2WI联合DWI及DCE对外周带慢性前列腺炎与前列腺癌的诊断效能分析\[J\]. 磁共振成像, 2020, 11(12): 1182-1185.
［19］Giganti F, Pecoraro M, Fierro D, et al. DWI and PRECISE criteria in men on active surveillance for prostate cancer: A multicentre preliminary experience of different ADC calculations\[J\]. Magn Reson Imaging, 2020, 67: 50-58.
［20］Stamatelatou A, Scheenen TWJ, Heerschap A. Developments in proton MR spectroscopic imaging of prostate cancer\[J\]. MAGMA, 2022, 35(4): 645-665.
［21］Guo Z, Qin X, Mu R, et al. Amide proton transfer could provide more accurate lesion characterization in the transition zone of the prostate\[J\]. J Magn Reson Imaging, 2022, 56(5): 1311-1319.
［22］Li M, Yang L, Yue Y, et al. Use of radiomics to improve diagnostic performance of PIRADS v2.1 in prostate cancer\[J\]. Front Oncol, 2020, 10: 631831.
［23］Harmon SA, Gesztes W, Young D, et al. Prognostic features of biochemical recurrence of prostate cancer following radical prostatectomy based on multiparametric MRI and immunohistochemistry analysis of MRIguided biopsy specimens\[J\]. Radiology, 2021, 299(3): 613-623.
［24］Schelb P, Kohl S, Radtke JP, et al. Classification of cancer at prostate MRI: deep learning versus clinical PIRADS assessment\[J\]. Radiology, 2019, 293(3): 607-617.
［25］Winkel DJ, Wetterauer C, Matthias MO, et al. Autonomous detection and classification of PIRADS lesions in an MRI screening population incorporating multicenterlabeled deep learning and biparametric imaging: proof of concept\[J\]. Diagnostics (Basel), 2020, 10(11): 951.
［26］Murthy V, Sonni I, Jariwala N, et al. The role of PSMA PET/CT and PET/MRI in the initial staging of prostate cancer\[J\]. Eur Urol Focus, 2021, 7(2): 258-266.
［27］Tay KJ, Gupta RT, Holtz J, et al. Does mpMRI improve clinical criteria in selecting men with prostate cancer for active surveillance?\[J\]. Prostate Cancer Prostatic Dis, 2017, 20(3): 323-327.
［28］Turkbey B, Mani H, Aras O, et al. Prostate cancer: can multiparametric MR imaging help identify patients who are candidates for active surveillance?\[J\]. Radiology, 2013, 268(1): 144-152.
［29］庄君龙,尹皓立,阚延晟,等.经会阴前列腺靶向穿刺和系统穿刺与根治术后病理结果的一致性分析\[J\].江苏大学学报（医学版）, 2020, 30(4): 361-363,368.
［30］Ploussard G, Beauval JB, Lesourd M, et al. Performance of systematic, MRItargeted biopsies alone or in combination for the prediction of unfavourable disease in MRIpositive lowrisk prostate cancer patients eligible for active surveillance\[J\]. World J Urol, 2020, 38(3): 663-671.
［31］Nahar B, Katims A, Barboza MP, et al. Reclassification rates of patients eligible for active surveillance after the addition of magnetic resonance imagingultrasound fusion biopsy: an analysis of 7 widely used eligibility criteria\[J\]. Urology, 2017, 110: 134-139.
［32］Schaeffer E, Srinivas S, Antonarakis ES, et al. NCCN Guidelines insights: prostate cancer, version 1.2021\[J\]. J Natl Compr Canc Netw, 2021, 19(2): 134-143.
［33］Moore CM, Giganti F, Albertsen P, et al. Reporting magnetic resonance imaging in men on active surveillance for prostate cancer: the PRECISE recommendations—a report of a european school of oncology task force\[J\]. Eur Urol, 2017, 71(4): 648-655.
［34］Caglic I, Sushentsev N, Gnanapragasam VJ, et al. MRIderived PRECISE scores for predicting pathologicallyconfirmed radiological progression in prostate cancer patients on active surveillance\[J\]. Eur Radiol, 2021, 31(5): 2696-2705.
［35］Eineluoto JT, Jrvinen P, Kenttmies A, et al. Repeat multiparametric MRI in prostate cancer patients on active surveillance\[J\]. PLoS One, 2017, 12(12): e0189272.
［36］Perlis N, AlKasab T, Ahmad A, et al. Defining a cohort that may not require repeat prostate biopsy based on PCA3 score and magnetic resonance imaging: the dual negative effect\[J\]. J Urol, 2018, 199(5): 1182-1187.
［37］Klotz L, Pond G, Loblaw A, et al. Randomized study of systematic biopsy versus magnetic resonance imaging and targeted and systematic biopsy in men on active surveillance (ASIST): 2year postbiopsy followup\[J\]. Eur Urol, 2020, 77(3): 311-317.
［38］Stavrinides V, Giganti F, Emberton M, et al. MRI in active surveillance: a critical review\[J\]. Prostate Cancer Prostatic Dis, 2019, 22(1): 5-15.
［39］Stavrinides V, Giganti F, Trock B, et al. Fiveyear outcomes of magnetic resonance imagingbased active surveillance for prostate cancer: a large cohort study\[J\]. Eur Urol, 2020, 78(3): 443-451.
［40］Gallagher KM, Christopher E, Cameron AJ, et al. Fouryear outcomes from a multiparametric magnetic resonance imaging (MRI)based active surveillance programme: PSA dynamics and serial MRI scans allow omission of protocol biopsies\[J\]. BJU Int, 2019, 123(3): 429-438.